News Releases

Year

16 Sep '22

Quince Therapeutics Presents Preclinical Data at MHSRS 2022 Demonstrating Preclinical Efficacy of Bone-targeting Platform for Traumatic Bone Injury

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Sep. 16, 2022-- Quince Therapeutics, Inc. (Nasdaq: QNCX), a biopharmaceutical company advancing innovative precision therapeutics targeting debilitating and rare diseases, today detailed highlights from the company’s participation at the Military

PDF Version

12 Sep '22

Quince Therapeutics Presents Preclinical Data at ASBMR 2022 Demonstrating Application of Bone-targeting Platform for Spinal Fusion and Bone Cancer Indications

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Sep. 12, 2022-- Quince Therapeutics, Inc. (Nasdaq: QNCX), a biopharmaceutical company advancing innovative precision therapeutics targeting debilitating and rare diseases, today detailed highlights from the company’s participation at The American

PDF Version

30 Aug '22

Quince Therapeutics Presents Preclinical Data at OI 2022 Demonstrating Potential of a Targeted Anabolic for Accelerated Bone Healing of Osteogenesis Imperfecta Fractures

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Aug. 30, 2022-- Quince Therapeutics, Inc. (Nasdaq: QNCX), a biopharmaceutical company advancing innovative precision therapeutics targeting debilitating and rare diseases, today presented preclinical data at the 14 th International Conference on

PDF Version

25 Aug '22

Quince Therapeutics to Present at Upcoming Scientific Meetings

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Aug. 25, 2022-- Quince Therapeutics, Inc. (Nasdaq: QNCX), a biopharmaceutical company advancing innovative precision therapeutics targeting debilitating and rare diseases, announced that the company will present at a number of scientific meetings

PDF Version

04 Aug '22

Quince Therapeutics to Present at Canaccord Genuity 42nd Annual Growth Conference on August 11, 2022

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Aug. 4, 2022-- Quince Therapeutics, Inc. (Nasdaq: QNCX), a biopharmaceutical company advancing innovative precision therapeutics targeting debilitating and rare diseases, today announced that the company’s chief executive officer Dirk Thye , M.D., will

PDF Version

01 Aug '22

Quince Therapeutics Details Strategic Growth Plan with Launch of New Corporate Name

Strategic focus centered on advancing innovative precision therapeutics for debilitating and rare diseases Highly differentiated bone-targeting drug platform and lead precision bone growth molecule NOV004 to address underserved therapeutic areas with major, unmet medical needs Pursuing strategic

PDF Version

27 Jul '22

Cortexyme Corporate Name Change to Quince Therapeutics to Take Effect on August 1, 2022

New ticker symbol (Nasdaq: QNCX) to initiate trading on August 1, 2022 SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jul. 27, 2022-- Cortexyme, Inc. (Nasdaq: CRTX) today announced that the company’s planned corporate name change to Quince Therapeutics is expected take effect on Monday, August 1,

PDF Version

27 Jul '22

Cortexyme Successfully Completes Phase 1 Single and Multiple Ascending Dose Clinical Trial of COR588

Once daily dose of COR588 over 10-day period well-tolerated with no serious adverse events observed SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jul. 27, 2022-- Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company focused on advancing therapeutics for rare and degenerative

PDF Version

21 Jun '22

Cortexyme Announces Preclinical Data Demonstrating Efficacy of COR803 for the Treatment of Coronavirus Infections

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jun. 21, 2022-- Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company focused on advancing therapeutics for rare and degenerative diseases, today announced new preclinical data demonstrating the efficacy of the company’s 3CLpro

PDF Version

13 Jun '22

Cortexyme Appoints June Bray to its Board of Directors

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jun. 13, 2022-- Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company focused on rare and degenerative diseases, today announced the appointment of June Bray , a pharmaceutical industry veteran and global drug development and

PDF Version

Pagination

Current page 1
Page 2
Page 3
Next page
Last page

Displaying 1 - 10 of 22